2024 Thematic Discussions on the Implementation of All International Drug Policy Commitments, Following-up to the 2019 Ministerial Declaration Chair: Good Morning. Secretariat: (organizational matters + scheduling 101) Moderator/intro: Mr. Justice Tettey, Chief, Drugs, Laboratory and Scientific Services Branch, UNODC: Good morning, dear colleagues. Thank you for this opportunity to address the question you posed about …
2024 Thematic Discussions on the Implementation of All International Drug Policy Commitments, Following-up to the 2019 Ministerial Declaration Chair: Hello, good afternoon, everyone. Welcome back. Let’s begin the afternoon session. Introductory remarks: Mr. Michael Osman, Social Affairs Officer, Border Management Branch, UNODC: I’ll provide a brief overview to leave more time for our interactive discussions …
CND Intersessional meeting – Thematic discussions on the implementation of all international drug policy commitments following up to the 2019 Ministerial Declaration Secretariat: (administrative and organizational issues) Chair: Welcome. The topics of the three days of this meeting are identified in the 2019 declaration. One of the challenges is the funding and diversification of drug …
Chair: We will consider scheduling recommendations by WHO and INCB. CND Secretariat: Recalls the substances and scheduling recommendations. Chair: Explains process to schedule substances under 1961, 1971 and 1988 conventions. Butonitazene WHO: Butonitazene, or butoxynitazene, is a benzimidazole-derived synthetic opioid not currently under international control and lacking recognized therapeutic use. It appears as a crystalline …
(c) International Narcotics Control Board Colombia: (TBA) Pakistan: Pakistan acknowledges and appreciates the effective role and efforts of the INCB in the collection of data, in-depth analysis, and compilation of the comprehensive report. We believe that the INCB report for 2023 will provide assistance to member states in aligning their national priorities and responses to …
Chair: First and foremost, I would like to welcome you to the first intersessional meeting of a CND during this ssession. To start, I want to ensure that we’re aligned on the significant matters we’ve encountered, particularly regarding the outcome document. First of all though, the floor is the Secretariat’s. Secretariat: Thank you, Mr. Chair. Good …